ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Core Viewpoint - ALX Oncology is hosting a virtual event to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the CD47-blocker evorpacept in HER2-positive gastric cancer patients [1][4]. Group 1: Event Details - The virtual event will take place on January 23 at 1:00 p.m. PT/4:00 p.m. ET [1]. - The ASPEN-06 data will also be presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier that day [2]. - The presentation will be led by Dr. Kohei Shitara and will focus on the final analysis of the randomized phase 2 part of the ASPEN-06 study [3][4]. Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer [5]. - The lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications [5].